BioMarin Pharma's (BMRN) Q2 Revenue Tops Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. NRIX
8. SPY
9. BAC
10. SUNS

Go back to BioMarin Pharma's (BMRN) Q2 Revenue Tops Views

Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy

August 5, 2016 10:46 AM EDT

Jefferies reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $120.00 (from $116.00), following the company's 2Q earnings report.

Analyst Eun Yang commented, "Higher 2Q revenue on higher Vimizim & Kuvan sales. With Naglazyme, Kuvan & Vimizim sales running... More

BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

August 5, 2016 9:01 AM EDT

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $107.00) following Q2 results and raised guidance.

Schimmer commented, "After the close, BMRN reported strong 2Q results and raised FY2016... More